ContraVir Pharmaceuticals Inc (CTRV) Shares Sold by TIAA CREF Investment Management LLC

ContraVir Pharmaceuticals Inc (CTRV) Shares Sold by TIAA CREF Investment Management LLC

TIAA CREF Investment Management LLC decreased its stake in ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) by 0.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,037,567 shares of the biopharmaceutical company’s stock after selling 9,379 shares during the period. TIAA CREF Investment Management LLC owned about 1.93% of ContraVir Pharmaceuticals worth $5,717,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in CTRV. Prospera Financial Services Inc raised its stake in shares of ContraVir Pharmaceuticals by 8.5% in the third quarter. Prospera Financial Services Inc now owns 193,800 shares of the biopharmaceutical company’s stock valued at $207,000 after buying an additional 15,250 shares during the period. Teachers Advisors Inc. raised its stake in shares of ContraVir Pharmaceuticals by 95.2% in the second quarter. Teachers Advisors Inc. now owns 289,919 shares of the biopharmaceutical company’s stock valued at $1,102,000 after buying an additional 141,368 shares during the period. Finally, Vanguard Group Inc. raised its stake in shares of ContraVir Pharmaceuticals by 8.7% in the second quarter. Vanguard Group Inc. now owns 915,369 shares of the biopharmaceutical company’s stock valued at $952,000 after buying an additional 73,135 shares during the period. 4.98% of the stock is currently owned by institutional investors and hedge funds.

Shares of ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) traded down 1.38% on Friday, hitting $1.43. The company had a trading volume of 189,559 shares. ContraVir Pharmaceuticals Inc has a 12 month low of $0.81 and a 12 month high of $2.65. The company has a 50-day moving average of $1.51 and a 200 day moving average of $1.45. The stock’s market cap is $85.72 million.

Separately, Maxim Group reissued a “buy” rating and set a $4.00 price target on shares of ContraVir Pharmaceuticals in a research note on Thursday, October 13th.

About ContraVir Pharmaceuticals

ContraVir Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development of antiviral drugs for the treatment of Hepatitis B virus (HBV) infections. The Company develops a range of compounds to treat HBV infection, which include CMX157 and CRV431. The Company is also developing an antiviral asset, FV-100.

Want to see what other hedge funds are holding CTRV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ContraVir Pharmaceuticals Inc (NASDAQ:CTRV).

Related posts

Leave a Comment